Mark Woodcock

10PUBLICATIONS
41CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 12, 2026
Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma.

|Jun 05, 2026
High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.

|Jul 21, 2025
A simple and efficient method for the robust expansion of human ILC2s to prevent acute GVHD.

Danny W Bruce, Sonia J Laurie, Yan Xing

|Jan 08, 2025
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells.

Feifei Song, Ourania Tsahouridis, Simone Stucchi

|Oct 01, 2024
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms.

Xin Zhou, Ying Wang, Zhangqi Dou

|Jun 18, 2024
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.

Elisa Landoni, Mark G Woodcock, Gabriel Barragan

Pageof 2

Frequent Collaborators

4 joint publications

Gianpietro Dotti

3 joint publications

Ourania Tsahouridis

3 joint publications

Giulia Casorati

3 joint publications

Paolo Dellabona